Group 1 - The innovation drug ETF (560900) has seen a rise of 2.64% with a trading volume of 14.26 million yuan, indicating active market participation [1] - The CSI Innovation Drug Industry Index (931152) increased by 2.86%, with notable gains from stocks such as Jiuzhou Pharmaceutical (603456) up 9.17%, Tigermed (300347) up 8.60%, and WuXi AppTec (603259) up 6.70% [1] - As of July 28, the latest scale of the innovation drug ETF reached 61.85 million yuan, with a total of 62.97 million shares, both marking a six-month high [1] Group 2 - The National Healthcare Security Administration announced that the 11th batch of centralized procurement will optimize specific rules, moving away from solely relying on the lowest bid, which is expected to alleviate excessive competition in the pharmaceutical industry [2] - Domestic CRO and CDMO sectors are benefiting from the global recovery of innovative drugs, with leading companies like WuXi AppTec and WuXi Biologics reporting strong mid-year performance [2] - The CSI Innovation Drug Industry Index reflects the overall performance of up to 50 representative listed companies involved in innovative drug research and development [2]

Group 1 - The core viewpoint of the news highlights the positive market response and policy support for the innovative drug sector, particularly through the recent ETF performance and government procurement policies [1][2]. - The innovative drug ETF (560900) experienced a significant increase in trading volume and net inflow of funds, reaching a new high in both scale and shares [1]. - The National Medical Insurance Administration has initiated the 11th batch of centralized drug procurement, establishing clear guidelines that protect innovative drugs, thereby boosting confidence in R&D and commercialization for innovative drug companies [2]. Group 2 - The new procurement policy is expected to enhance the commercialization path for innovative drugs, facilitating market penetration and sales growth [2]. - The innovative drug ETF closely tracks the CSI Innovative Drug Industry Index, which includes a maximum of 50 representative listed companies involved in innovative drug R&D [2]. - Morgan Asset Management is integrating its global technology investment products to help investors capitalize on opportunities in quality tech companies amid the rise of AI-driven technological advancements [2].